Doru Roiban
Keith Mulholland
Keith was born in and grew up in Liverpool. He obtained his first degree in 1985 at the University of Manchester Institute of Science and Technology, followed by a PhD at the same institution working for Professor Dick Stoodley on C-Nucleoside Synthesis. A Post-Doctoral Fellowship at the University of Texas at Austin working for Professor Philip Magnus on Alkaloid synthesis followed.
He returned to the UK in 1990 to take up a position as a Medicinal Chemist at SmithKline Beecham Harlow working on Serotonin Antagonists for the treatment of Irritable Bowel Syndrome and Depression. In 1996 he moved to the Synthetic Chemistry Department and started work in the area of Process Development.
Following the merger of SmithKline Beecham and Glaxo-Wellcome in 2001, Keith moved to Process R&D AstraZeneca Macclesfield. In his time there he has held various roles. He was the Lead Chemist for the Olaparib project from 2006-2007 and the Catalysis Technology Leader from 2008 to 2011.
Since 2011 he has been the Associate Principal Scientist and Departmental Lead for Biocatalysis within Pharmaceutical Technology and Development.
Andreas Liese
Valentin Nenov
Byron Silva
PROFILE:
- Veterinary with expertise for over 35 years in veterinary products segment working for local and global players. Previous experience in several areas of veterinary industry: vaccine production, QC, R&D, product manager, technical assistance and regulatory affairs.
- Support for technical and regulatory affairs for new and existing business.
- Support for development of new businesses in Brazil for global players.
